Kanan Pujara

About Kanan Pujara

PUBLICATION: Sensitivity to Anti-tubulin Chemotherapeutics is Regulated by Mcl–1 and FBW7. Nature volume 471, pages 110–114 Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010 Aug 12;46•••08):869-73. Epub 2010 Jul 28 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510-22. Epub 2010 Apr 15. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medullablastoma. Science 2009 oct 23:32•••52):572-4. Epub 2009 Sep 2 Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res. 2007 Oct 1;67(19):9591-6. Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection. Nat Methods. 2007 Sep;4(9):713-5. Epub 2007 Aug 19. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006 Jan 1;66(1):283-9. Spectrum of sequence variations in the FANCA gene: an International Fanconi Anemia Registry (IFAR) study. Hum Mutat. 2005 Feb;25(2):142-9. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst. 2003 Nov 19;95(22):1718-21 Spectrum of sequence variation in the FANCG gene: an International Fanconi Anemia Registry (IFAR) study. Human Mutations 21:15••••••03). Genetic classification of African – American Fanconi Anemia Patients in the International Fanconi Anemia Registry (IFAR). Blood 2001 NOV 16; 98(11): 216A-217A The Fanconi Anemia Mutation Database: American Journal of Human Genetics 2001 OCT; 69(4):612. In situ Reproductive rate of freshwater Caulobacter spp. Applied Environmental Microbiology. Sep.

Experience

1. Technical Sales Manager

   Integrated DNA Technologies

   Dec 2021 — Present · San Francisco, CA, US

   Built and nurtured long-term relationships with major biotech firms, contributing to multi-million-dollar revenue streams through tailored solutions in RUO and GMP environments.• Led key account management for complex, multi-million-dollar OEM partnerships, ensuring sustained growth by addressing evolving client needs.• Facilitated the transition of clients from RUO to GMP, scaling operations and ensuring compliance, resulting in substantial long-term contracts.• Consistently surpassed sales targets, achieving over 20% above annual goals.• Awarded Gold and Silver accolades as a top performer for three consecutive years.• Managed and expanded the Peninsula and South Bay Area territory, establishing and maintaining strategic relationships with major biotech firms, start-ups, and academic institutions.• Developed lasting relationships, expanding client revenues from to $4-5 million.• Achieved over 50% growth in NGS, CRISPR, and synthetic biology product sales.• Utilized SalesForce, LinkedIn Navigator, and GenomeWeb for effective prospecting and sales funnel management.• Leveraged PowerBI to analyze purchasing trends and evaluate product line performance- Prospect and manage the sales funnel to meet short- and long-term sales objectives, using SalesForce, LinkedIn Navigator, GenomeWeb and other tools- Analyze the territory on PowerBI to find purchasing trends, evaluating sales for individual product line, and assessing downward trends of individual organizations- Analyze the market for new products, new technology and customer investments.

Education

• Barnard College

  BS, Biology

  1995 — 1999

• University of Pennsylvania

  Masters, Molecular Biotechnology

  1999 — 2001

Skills

• Sequencing
• Genomics
• Biotechnology
• Genetics
• Molecular Biology
• Primer Design
• Laboratory
• Cancer
• Cell
• Ngs
• Science
• Dna
• Dna Sequencing
• Bioinformatics
• Sequence Analysis
• Assay Development
• Pcr
• Protein Chemistry
• Life Sciences